Altimmune (ALT) Profit After Tax (2010 - 2026)
Altimmune (ALT) reported Profit After Tax of -$22.6 million for Q1 2026, down 15.26% year-over-year from -$26.6 million in Q1 2025, and up 17.53% quarter-over-quarter from -$27.4 million in Q4 2025.
Altimmune (ALT) Profit After Tax (2010 - 2026) Analysis & Trends
Altimmune (ALT) has 17 years of Profit After Tax data on file, last reported at -$22.6 million in Q1 2026.
- Profit After Tax for Q1 2026 came in at -$22.6 million, down 15.26% year-over-year; the trailing twelve-month figure through Mar 2026 was -$91.1 million (down 0.93% YoY), and the FY2025 annual result was -$88.1 million, up 7.33% from the prior year.
- Profit After Tax climbed to -$22.6 million in Q1 2026 per ALT's latest filing, from -$27.4 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$16.1 million in Q2 2023 and troughed at -$31.6 million in Q4 2023.
- A 5-year average of -$22.3 million and a median of -$22.1 million in 2025 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2022 and 2024: Profit After Tax grew 29.82% in 2022, then slumped 53.42% in 2024.
- A 5-year view of Profit After Tax shows it stood at -$21.7 million in 2022, then tumbled by 46.08% to -$31.6 million in 2023, then advanced by 26.74% to -$23.2 million in 2024, then retreated by 18.02% to -$27.4 million in 2025, then gained by 17.53% to -$22.6 million in 2026.
- Business Quant data shows ALT's Profit After Tax at -$22.6 million in Q1 2026, -$27.4 million in Q4 2025, and -$19.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Altimmune | 336.67 Mn | 336.67 Mn | - | -22.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.56 Mn |
| Dec 31, 2025 | -27.36 Mn |
| Sep 30, 2025 | -19.01 Mn |
| Jun 30, 2025 | -22.15 Mn |
| Mar 31, 2025 | -19.58 Mn |
| Dec 31, 2024 | -23.18 Mn |
| Sep 30, 2024 | -22.85 Mn |
| Jun 30, 2024 | -24.64 Mn |
| Mar 31, 2024 | -24.39 Mn |
| Dec 31, 2023 | -31.64 Mn |
| Sep 30, 2023 | -20.67 Mn |
| Jun 30, 2023 | -16.06 Mn |
| Mar 31, 2023 | -20.07 Mn |
| Dec 31, 2022 | -21.66 Mn |
| Sep 30, 2022 | -23.52 Mn |
| Jun 30, 2022 | -20.11 Mn |
| Mar 31, 2022 | -19.43 Mn |
| Dec 31, 2021 | -23.89 Mn |
| Sep 30, 2021 | -33.51 Mn |
| Jun 30, 2021 | -24.83 Mn |